Archil Jaliashvili/LinkedIn
Oct 11, 2026, 14:54
Archil Jaliashvili: NHSBT Highlights Persistent Gaps in Matched Blood for Sickle Cell Patients
Archil Jaliashvili, Co-Chief Executive Officer at GeoBio Pharm, Biotech Executive, Strategic Partner of BHOC and Precision Oxygen Therapeutics, shared a post on X:
“NHSBT reports that only around half of the matched blood demand for patients with sickle cell on regular transfusions can currently be met.
This is a compatibility challenge, not simply a shortage of units.
Our analysis.”
Other posts featuring Archil Jaliashvili on Hemostasis Today.
-
Oct 11, 2026, 16:03Parth Parmar: Practical Guidelines for Managing Venous Thromboembolism
-
Oct 11, 2026, 15:31Muhammad Alvi: CASPR Study Explores Treatment Response Across ESUS Phenotypes
-
Oct 11, 2026, 15:15Thalassaemia International Federation Joins ASCAT 2026 to Advance Sickle Cell and Thalassaemia Care
-
Oct 11, 2026, 15:14Challenges and Perspectives on Gene Therapy in Hemophilia A – Seminars in Thrombosis and Hemostasis
-
Oct 11, 2026, 15:07Neysa Rahardjo: Platelet Estimation Pitfalls and Discrepancy Resolution
-
Oct 11, 2026, 15:05Lance Trewhella: Reflections from the ASCLS Region V Fall Symposium
-
Oct 11, 2026, 15:04The Anti-Inflammatory Rationale for GLP-1 Agonists in Hemophilia – CRH French Reference Center for Hemophilia Lyon
-
Oct 11, 2026, 15:00Donja W.: Blood Shortages Aren’t Just Statistics
-
Oct 11, 2026, 14:46Sebastien Lobet: Physiotherapy and Joint Health Across the Spectrum of Bleeding Disorders